Shares of Ardelyx (NASDAQ: ARDX) are hitting a new all-time low following the results of a "positive" phase 3 trial read out earlier this month. While shares of competitor Synergy Pharmaceuticals (NASDAQ: SGYP) saw a slight increase the day of Ardelyx's announcement, Synergy has fared little better, with shares down almost to their lowest point this year.ARDX data by YChartsContinue reading